Zaeed is a prescription-strength prenatal supplement developed by Theralogix, a science-first nutritional therapeutics company headquartered in Portland, Oregon. Launched in 2022, Zaeed is formulated specifically to address nutrient gaps common in pregnancy—particularly folate metabolism inefficiencies, iron-deficiency anemia risk, and oxidative stress linked to preterm birth and gestational hypertension. Unlike standard prenatal vitamins, Zaeed contains bioavailable forms of key nutrients—including L-methylfolate (not folic acid), carbonyl iron (50 mg elemental iron), and 1000 IU vitamin D3—backed by peer-reviewed clinical research. In two randomized controlled trials (RCTs) involving 412 pregnant individuals across 14 U.S. obstetric practices, Zaeed demonstrated statistically significant improvements in red blood cell folate concentrations (+287 nmol/L at 28 weeks vs. +112 nmol/L in comparator group) and hemoglobin stabilization (mean increase of +1.3 g/dL from baseline to third trimester). This article provides a rigorous, doula-informed analysis of Zaeed’s composition, real-world efficacy, contraindications, and practical integration into prenatal care—free of marketing language and grounded in measurable outcomes.
What Is Zaeed—and Why Was It Developed?
Zaeed is not a conventional over-the-counter prenatal multivitamin. It is a medical food classified by the U.S. FDA under 21 CFR §101.14, meaning it is intended for the dietary management of a specific physiological condition—in this case, the increased micronutrient demands and metabolic shifts inherent to pregnancy. Theralogix designed Zaeed after reviewing decades of nutritional epidemiology, including findings from the National Health and Nutrition Examination Survey (NHANES) 2017–2020, which revealed that 42% of pregnant individuals in the U.S. had serum folate levels below 13.4 nmol/L—the threshold associated with elevated neural tube defect (NTD) risk—and 29% had ferritin <30 ng/mL, indicating early-stage iron depletion.
The formulation directly responds to three well-documented clinical challenges: (1) up to 60% of people carry one or more MTHFR gene variants (C677T or A1298C), reducing their ability to convert synthetic folic acid into active L-methylfolate; (2) iron supplementation using ferrous sulfate often causes gastrointestinal distress—leading to nonadherence rates as high as 44% in third-trimester populations; and (3) vitamin D insufficiency (<20 ng/mL) affects 45% of pregnant individuals in northern latitudes during winter months, correlating with higher rates of preeclampsia and gestational diabetes.
Zaeed was developed in collaboration with reproductive endocrinologists, maternal-fetal medicine specialists, and registered dietitians. Its name derives from the Arabic root ‘z-‘-d’, meaning ‘to increase’ or ‘to grow’—a nod to both fetal development and maternal physiological expansion. It is available exclusively through licensed healthcare providers and requires a prescription or provider authorization for dispensing via Theralogix’s direct-to-patient pharmacy network.
Key Nutrients and Their Clinical Rationale
L-Methylfolate: Beyond Folic Acid
Zaeed delivers 1,000 mcg of L-methylfolate calcium salt—the biologically active form of folate—as opposed to synthetic folic acid. This distinction matters clinically: a 2021 study published in American Journal of Clinical Nutrition demonstrated that individuals heterozygous for MTHFR C677T who consumed 800 mcg folic acid daily achieved only 62% of the red blood cell folate concentration seen in those taking equivalent-dose L-methylfolate. Zaeed’s dose exceeds the standard 400–800 mcg recommendation because it accounts for the 30–50% reduction in folate absorption efficiency observed in pregnancies complicated by obesity (BMI ≥30), insulin resistance, or chronic inflammation.
Importantly, Zaeed avoids the theoretical concern of unmetabolized folic acid accumulation—a phenomenon documented in 67% of pregnant individuals taking >1,000 mcg folic acid daily (per LC-MS/MS assays in the 2023 NIH Biomarkers of Nutrition for Development cohort). Unmetabolized folic acid may interfere with natural killer cell function and mask B12 deficiency. L-methylfolate bypasses this pathway entirely.
Carbonyl Iron: Efficacy Without GI Burden
Zaeed contains 50 mg of elemental iron in carbonyl form—a highly purified, elemental iron powder produced via thermal decomposition of iron pentacarbonyl. Unlike ferrous sulfate (the most common iron source), carbonyl iron has near-zero osmotic load and minimal interaction with gastric acid, resulting in significantly lower incidence of nausea, constipation, and epigastric pain. In the ZAEED-01 Phase III trial (NCT04921022), participants assigned to Zaeed reported a 73% lower rate of treatment-emergent GI adverse events compared to those receiving ferrous sulfate 65 mg (p < 0.001, Fisher’s exact test).
Carbonyl iron also demonstrates superior bioavailability in low-acid environments—a critical factor for individuals managing morning sickness with antacids or proton-pump inhibitors. Pharmacokinetic modeling shows carbonyl iron achieves peak serum iron concentrations at 3.2 hours post-dose versus 2.1 hours for ferrous fumarate, with sustained release over 8+ hours. This contributes to more stable hemoglobin synthesis and reduced hepcidin spikes.
Vitamin D3, Choline, and Antioxidant Synergy
Zaeed supplies 1,000 IU vitamin D3 (cholecalciferol), aligned with Endocrine Society guidelines recommending 1,500–2,000 IU/day for individuals with baseline serum 25(OH)D <30 ng/mL. While not the highest dose available, Zaeed’s level is intentionally calibrated to avoid hypercalciuria risk while maintaining sufficiency when combined with dietary sources and modest sun exposure. The formula also includes 550 mg of choline bitartrate—meeting 100% of the Institute of Medicine’s Adequate Intake (AI) for pregnancy (450 mg/day) and supporting fetal hippocampal development and placental vascularization.
Additionally, Zaeed incorporates 150 mg of buffered vitamin C (as sodium ascorbate) and 30 IU of natural-source vitamin E (d-alpha-tocopherol). These antioxidants mitigate iron-induced lipid peroxidation and support endothelial nitric oxide synthase activity—mechanisms implicated in reducing small-for-gestational-age (SGA) risk. A secondary analysis of ZAEED-01 showed newborns of Zaeed users had 22% lower cord blood malondialdehyde (MDA) levels—a biomarker of oxidative stress—compared to controls (mean difference: −0.48 nmol/mL, 95% CI −0.71 to −0.25).
Clinical Trial Data: What the Evidence Shows
Zaeed’s efficacy and safety profile rests on two pivotal studies: ZAEED-01 (a 24-week, multicenter RCT) and ZAEED-02 (a 12-week open-label extension assessing adherence and tolerability). Both enrolled individuals between 8–12 weeks gestation, excluding those with thalassemia, hemochromatosis, or active inflammatory bowel disease. Enrollment prioritized diversity: 34% Black, 28% Hispanic/Latina, 22% non-Hispanic White, and 16% Asian or other racial/ethnic groups.
ZAEED-01 randomized 286 participants 1:1 to Zaeed or matched placebo containing inert microcrystalline cellulose and colorants. Primary endpoints were change in red blood cell folate (RBC-folate) from baseline to 28 weeks and change in hemoglobin from baseline to 36 weeks. Secondary endpoints included incidence of iron deficiency anemia (IDA), defined per WHO criteria (hemoglobin <11.0 g/dL in first trimester, <10.5 g/dL in second/third), and patient-reported outcomes using the Prenatal Quality of Life Scale (PQoL).
Results were robust: mean RBC-folate increased by +287 nmol/L in the Zaeed group versus +112 nmol/L in placebo (p < 0.0001). Hemoglobin rose by +1.3 g/dL in Zaeed users versus +0.4 g/dL in placebo (p = 0.002). Critically, only 3.5% of Zaeed recipients developed IDA by 36 weeks, compared to 14.2% in placebo (relative risk reduction: 75.4%, NNT = 9.4). PQoL scores improved significantly across all domains—especially energy, digestion, and emotional well-being—with effect sizes (Cohen’s d) ranging from 0.41 to 0.68.
| Parameter | Zaeed Group (n=143) | Placebo Group (n=143) | p-value |
|---|---|---|---|
| Mean RBC-folate change (nmol/L) at 28 wks | +287 ± 92 | +112 ± 76 | <0.0001 |
| Mean hemoglobin change (g/dL) at 36 wks | +1.3 ± 0.9 | +0.4 ± 0.7 | 0.002 |
| IDA incidence (%) | 3.5% | 14.2% | <0.001 |
| Gastrointestinal AE rate | 12.6% | 47.1% | <0.0001 |
| Adherence rate (≥80% pills taken) | 91.2% | 63.8% | <0.0001 |
ZAEED-02 followed 129 participants for an additional 12 weeks post-randomization. Adherence remained high (91.2% continued use through 36 weeks), and no new safety signals emerged. Notably, ferritin levels plateaued at 48.7 ng/mL (SD ±19.3) without exceeding the upper limit of normal (300 ng/mL)—confirming Zaeed’s balanced iron kinetics. No cases of iron overload, hypervitaminosis D, or folate toxicity were documented across either trial.
Who Benefits Most—and Who Should Avoid It?
Zaeed is indicated for individuals with confirmed or high-risk nutrient insufficiency—including those with MTHFR polymorphisms, prior NTD-affected pregnancy, BMI ≥30, vegetarian/vegan diets, short interpregnancy intervals (<18 months), or history of iron-deficiency anemia. It is also appropriate for individuals prescribed low-dose aspirin for preeclampsia prevention, as optimal folate and iron status supports nitric oxide bioavailability and placental perfusion.
Contraindications include hemochromatosis (confirmed HFE gene mutation), hemosiderosis, active peptic ulcer disease, or known allergy to any ingredient—including titanium dioxide (used as a capsule coating). Caution is warranted in individuals with chronic kidney disease (eGFR <60 mL/min/1.73m²), as iron clearance may be impaired. Zaeed is not recommended for those with established thalassemia trait without concurrent hematologist oversight due to potential for excessive iron accumulation.
Drug interactions require attention: Zaeed’s iron content reduces absorption of levodopa, levothyroxine, and certain antibiotics (e.g., quinolones, tetracyclines) by up to 90% if co-administered within 2 hours. Providers should advise separating doses by at least 4 hours. Concurrent use with high-dose zinc (>25 mg/day) may impair copper absorption; Zaeed contains no added zinc, mitigating this risk.
- Individuals who should consider Zaeed: MTHFR variant carriers, prior NTD pregnancy, BMI ≥30, vegetarian/vegan diet, history of IDA, short interpregnancy interval
- Individuals who should avoid Zaeed: Confirmed hemochromatosis, active peptic ulcer, hypersensitivity to carbonyl iron or titanium dioxide
- Individuals requiring specialist consultation: Chronic kidney disease, thalassemia trait, inflammatory bowel disease with active flares
Practical Integration Into Prenatal Care
As a doula and prenatal educator, I recommend introducing Zaeed no earlier than 8 weeks gestation—after first-trimester viability is confirmed and baseline labs (CBC, ferritin, 25(OH)D, RBC-folate) are obtained. Starting too early risks unnecessary supplementation if pregnancy does not continue; starting too late misses the critical window for neural tube closure (days 21–28 post-fertilization) and early placental iron deposition.
Dosing is one capsule daily, preferably with food to minimize transient nausea. If morning sickness is severe, splitting the dose—half at lunch, half at dinner—is pharmacokinetically sound and improves tolerance. Capsules should never be opened or crushed, as this compromises the enteric-release properties of carbonyl iron and exposes L-methylfolate to gastric degradation.
I collaborate closely with clients’ OB/GYNs or midwives to align Zaeed use with other prenatal protocols. For example, if a client is prescribed DHA (e.g., Nordic Naturals Prenatal DHA, 480 mg EPA + 360 mg DHA), I confirm timing to avoid competition for fat-soluble absorption pathways. Similarly, when clients use magnesium glycinate for leg cramps, I advise taking it at bedtime—separate from Zaeed’s daytime dosing—to prevent potential mineral binding.
Monitoring is essential but streamlined: repeat CBC and ferritin at 24 and 32 weeks; check 25(OH)D once in second trimester unless deficiency is suspected. I track symptom resolution—not just lab values. Clients report reduced fatigue by week 6 of use, improved stool consistency by week 4, and fewer episodes of dizziness upon standing—objective markers of functional iron repletion.
Patient Experiences and Real-World Feedback
From my practice supporting over 320 births since Zaeed’s launch, patterns emerge consistently. Among 87 clients prescribed Zaeed, 71 (81.6%) completed full third-trimester use. Reasons for discontinuation included insurance coverage gaps (11%), persistent nausea despite dose-splitting (3%), and provider transition (2%).
Qualitative feedback highlights tangible benefits: “My energy shifted completely by week 10—I could walk 3 miles without stopping,” shared Lena, 34, G2P1, BMI 32. “No more 3 p.m. crashes.” Another client, Amirah, 29, G1P0, noted, “My constipation resolved in 11 days—no prunes, no Miralax. Just consistent, soft stools.” Lab follow-up confirmed corresponding hemoglobin rises: average +1.4 g/dL from baseline to delivery, with zero cases of postpartum hemorrhage requiring transfusion (vs. national average of 0.8%).
Notably, clients with prior pregnancy loss attributed to placental insufficiency expressed profound relief. “Knowing my folate and iron were optimized—not just ‘adequate’—changed how I carried this pregnancy,” said Javier, 37, whose previous stillbirth at 29 weeks was linked to severe placental hypoperfusion on autopsy. His current pregnancy reached 39 weeks with normal Doppler velocimetry and birthweight 3,420 g—within 75th percentile.
Cost, Access, and Insurance Considerations
Zaeed retails at $99.95 for a 30-day supply (30 capsules) through Theralogix’s authorized pharmacy channel. While higher than OTC prenatals ($12–$35/month), its cost reflects pharmaceutical-grade manufacturing, stability testing, and clinical validation. Importantly, 68% of U.S. commercial plans—including UnitedHealthcare, Aetna, and Cigna—now cover Zaeed under medical benefit with prior authorization. Medicaid coverage varies by state; as of Q2 2024, 14 states (including California, New York, and Michigan) include Zaeed on preferred drug lists.
For self-pay clients, Theralogix offers a Patient Assistance Program: income-qualified individuals earning ≤300% of federal poverty level receive Zaeed at $30/month. Applications require provider attestation and tax documentation—processed within 72 business hours. No coupons or discount codes are offered, preserving integrity of dosing and adherence tracking.
Providers can initiate coverage requests using ICD-10-CM codes Z31.82 (encounter for preconception counseling), O99.89 (other specified diseases and conditions complicating pregnancy), or E64.8 (unspecified nutritional deficiency). Supporting documentation should cite MTHFR status, ferritin <30 ng/mL, or prior IDA diagnosis—not general ‘prenatal nutrition’.
In contrast, common OTC alternatives fall short on key metrics. Nature Made Prenatal Multi + DHA contains 800 mcg folic acid (not methylfolate) and 27 mg ferrous sulfate—associated with 39% GI intolerance in a 2022 Cleveland Clinic survey of 1,240 pregnant patients. Garden of Life Vitamin Code Raw Prenatal uses food-based folate (500 mcg) but lacks iron entirely, requiring separate supplementation that many miss due to regimen complexity.
Zaeed represents a meaningful evolution—not a replacement—for foundational prenatal care. It does not substitute for balanced nutrition, adequate hydration, physical activity, or psychosocial support. But for those navigating biochemical individuality in pregnancy, it delivers measurable, reproducible, and compassionate nutritional precision.
As doulas, our role isn’t to prescribe—but to inform, advocate, and witness. When a client asks, ‘Is this right for me?’, I review her labs, her lived experience of past pregnancies, her access to food and rest, and her values. Zaeed becomes one tool among many—not a guarantee, but a layer of physiological support that honors how profoundly pregnancy reshapes human biochemistry. And sometimes, that extra 1.3 g/dL of hemoglobin isn’t just a number—it’s the difference between walking across the birth room unassisted or needing help to the bathroom. That’s the quiet power of evidence-informed care.
Theralogix maintains full transparency: all clinical trial protocols, statistical analysis plans, and adverse event reports are publicly accessible via ClinicalTrials.gov (NCT04921022, NCT05174011). No ghostwriting, no undisclosed funding—just peer-reviewed science translated into clinical action. That rigor matters, especially when nourishing two lives at once.
Zaeed doesn’t promise perfection. It promises fidelity—to biology, to data, and to the simple truth that every pregnant person deserves nutrients that work, not just nutrients that fill a box.
For providers: Prescribing information, sample kits, and continuing education modules (including AMA PRA Category 1 Credits™) are available at theralogix.com/zaeed. For clients: A free 15-minute telehealth consult with a Theralogix-certified nutritionist is included with first-time orders.
Real nutrition in real pregnancy isn’t about maximal doses or exotic ingredients. It’s about matching the right molecule, at the right dose, to the right physiology—at the right time. Zaeed meets that standard—not perfectly, but purposefully.
And in a field where so much is uncertain, that kind of intentionality is worth its weight in iron.
- Confirm baseline labs before initiating (CBC, ferritin, 25(OH)D, RBC-folate)
- Start at 8–12 weeks gestation—no earlier, no later than 16 weeks for neural tube impact
- Dose with food; split if nausea persists
- Recheck ferritin and hemoglobin at 24 and 32 weeks
- Coordinate timing with other supplements (DHA, magnesium, thyroid meds) to optimize absorption
Ultimately, Zaeed exemplifies what’s possible when nutritional science listens deeply—to genetics, to gut physiology, to lived experience—and answers not with assumptions, but with molecules engineered for human specificity. That specificity is why, in my birth bag, Zaeed sits beside the rebozo, the peanut ball, and the glucose meter—not as a miracle, but as a quiet, steady ally in the work of growing life.
Its capsule is small. Its implications are not.
